The modern era of cardiac surgery began in 1952 with the first clinical use of a form of total mechanical cardiac assist, the heart-lung machine, designed by John Gibbon. 4 Shortly thereafter, a totally artificial heart (TAH) developed by Drs. Willem Kolff and Tetsuzo Akutsu sustained a dog for 90 minutes. 5 In 1967, Dr. Adrian Kantrowitz described the first use of an intra-aortic balloon pump, 6 which to this day is the most widely used form of mechanical cardiac assist.
Indications and Timing
In broad terms, indications for use of an assist device include failure to wean from cardiopulmonary bypass, inability to safely bridge a patient to transplant using standard medical and surgical therapies, cardiogenic shock in both transplant and non-transplant candidates, and life-threatening arrhythmias not amenable to medical or surgical therapy. The threshold for placing an assist device is related to the comfort level and experience of the cardiovascular surgeon and cardiologist, the types of assist devices at their disposal, and the local standard of care. Specific guidelines are listed in the Table. At our institution, criteria for placement of an assist device are not absolute, and the choice to proceed is individualized to the patient. For example, a patient with a cardiac index of 1.8 L/min/m 2 who has relatively good blood pressure, has no end organ dysfunction, and is reasonably well perfused might not benefit from implantation of a LVAD. In comparison, a patient with a cardiac index of 1.8 L/min/m 2 , whose blood pressure is only 75/62 and serum sodium is 125, is likely to benefit from LVAD implantation.
While many patients with end stage heart disease have evidence of ongoing end organ dysfunction, implantation of a ventricular assist device is not contraindicated, provided that the dysfunction is not severe, or that it is believed to be reversible. For patients in whom the device is used as a bridge to transplantation, exclusion criteria are similar to the criteria used for transplant candidacy, with a few notable additions. For most devices, there is a patient size limit. For example, it is difficult to implant a Novacor ® or HeartMate ® if the body surface area of the patient is less than 1.5 m 2 , or a CardioWest ® TAH if the body surface area is <1.7 m 2 . These general guidelines are somewhat dependent on the body habitus of the patient as well.
Severe coagulopathy poses a substantial surgical challenge, and is a strong relative if not absolute contraindication to implantation of most forms of assist devices. Likewise, severe hepatic dysfunction is felt to be a contraindication to LVAD implantation, largely because of the resultant uncontrollable coagulopathy. In one series, preoperative hepatic dysfunction was the most consistent predictor of poor outcome. 11 We have used percutaneously placed extracorporeal membrane oxygenation (ECMO), more accurately known as extracorporeal life support (ECLS), to effect rapid and complete venous unloading, improve systemic perfusion, and optimize oxygen delivery, with the result of improvement in congestive hepatopathy and coagulopathy. With this strategy, the rate of LVAD survival after initial ECLS support of very high risk patients is not significantly different from the survival rate after LVAD placement alone in lower risk patients. 12 This strategy is also cost-effective because LVAD implantation, an expensive form of support, is not performed in those who do not survive the initial ECLS, which is a substantially less expensive option.
Profound or even complete renal dysfunction, although a risk factor for poor outcome, 13 
modialysis [CVVH-D], or hemodialysis).
In the setting of reversible renal dysfunction (such as acute tubular necrosis), substantial renal function usually returns within days to weeks after adequate perfusion is established by an assist device.
Appropriate timing for placement of a LVAD must be individualized to the patient. The window of opportunity is frequently narrow. The rule is to avoid implantation of a LVAD if it appears that standard medical therapy (for example, inotropes, diuretics, or implantable defibrillators) can safely bridge a patient to transplant. This assumes that during the waiting time for a donor organ, the patient can be active and mobile enough that adequate nutritional status, muscle mass, and strength are maintained, as severely debilitated patients have a much higher post-transplant mortality. If a reasonably appropriate physiology cannot be maintained, implantation of a LVAD is warranted. 14 Implantation of a LVAD results in normalization of end organ function, which facilitates recovery to a healthier state than that prior to transplantation. If implantation is delayed for too long, profound end organ dysfunction can render a patient too ill to survive the implantation procedure. A risk factor selection scale based on easy-to-obtain clinical and laboratory data has been developed to help identify patients at high risk for LVAD postoperative death. 15 In cases where risk is determined to be prohibitively high secondary to physiologic derangements, utilizing other means of ventricular support can help bridge the patient to a physiologic state compatible with LVAD implant survival. 12 Intra-aortic balloon counterpulsation, ECLS, and some of the extracorporeal devices can be extremely helpful in these situations.
We would like to think that economics should not play a role in deciding the most appropriate therapy for a patient. However, with the high cost of chronic intensive care, we are forced to consider the economics carefully. Despite the fact that an implantable LVAS is very costly, most of the cost is up front. Many of these patients can ultimately be discharged from the hospital to live at home, with minimal further cost. 16, 17 On the other hand, a single prolonged hospital admission, multiple hospital admissions, or home inotropic support, might in fact be even more costly. 18 Consider the patient who is likely to be chronically hospitalized, but is unlikely to be transplanted within a short period of time because of body size, blood type, or panel reactive antibody status. In this patient, utilization of a LVAS would be a clinically and economically sound decision.
Devices Most Commonly Used in the U.S.
There are many forms of mechanical circulatory assist devices. A few are available only at tertiary or transplant centers, but many are available at hospitals that have either a catheterization laboratory or cardiac surgery capability. Approximately 35% of our LVAS patients are placed on some form of ventricular or circulatory support prior to transfer to our institution. Our recent success with LVADs and transplantation is a tribute to other physicians' ability to identify, triage, and appropriately manage patients with profound cardiac disease. With this in mind, we feel that it is appropriate to review all forms of mechanical circulatory assist devices so that this practice might continue.
Intra-Aortic Balloon
Counterpulsation. This mode of ventricular assist is the most widely used form of mechanical ventricular support. Any form of left ventricular systolic dysfunction can be supported by the use of an intra-aortic balloon pump (IABP). An IABP can be used as a short-term bridge to recovery or transplant. One of the advantages of an IABP is that the device is reasonably portable, allowing hospital-to-hospital transfer without interruption of therapy. The major limitation is the relatively limited degree of support achieved with an IABP as compared to an implantable LVAD. Under optimal conditions, an IABP can increase cardiac index by only 15%-30%.
The IABP is usually emplaced percutaneously (occasionally by cut-down) via the femoral artery. Insertion can be performed in a cardiac catheterization laboratory, an operating room, and by skilled hands, at the bedside. The mechanism of action is dual. During diastole, balloon inflation augments aortic arterial pressure, with a resulting improvement in coronary perfusion. During systole, balloon deflation causes significant afterload reduction. The end result is improved myocardial and systemic oxygen delivery, decreased myocardial workload, and improved mean arterial pressure.
Contraindications to use of an IABP include severe aorto-ilio-femoral disease, aortic insufficiency, and aortic dissection. Risks include infection, bleeding, vascular trauma, embolization with loss of limb or end organ ischemia, and other difficulties caused by the immobilization required during support. The risk increases in proportion to duration of support, and because of this, an IABP is not the assist device of choice for long-term support. Systemic anticoagulation with heparin is generally required for prolonged use.
Extracorporeal Life Support (ECLS/ECMO).
These devices usually employ either roller pumps or centrifugal pumps in combination with a membrane oxygenator. The simplest form of this type of support is the heart-lung or cardiopulmonary bypass (CPB) machine, which can be used as a short-term bridge to a more permanent form of support. Longterm types of ECLS have largely been used in neonates and adults with acute respiratory distress syndrome. Although a few adult patients have been bridged to transplant with ECLS, the complications that occur with relatively brief support preclude its use for long-term ventricular support. It has been used as an effective short-term bridge to cardiac recovery. At other institutions 13 as well as our own, 12 the indications for ECLS has been extended to cardiac patients with profound end organ dysfunction as a bridge to LVAD implantation.
Advantages of this type of system include percutaneous cannulation, full oxygenation as well as perfusion, and weaning capabilities. It can completely unload the venous system, allowing for resolution of congestive hepatopathy and nephropathy. Various forms of dialysis can be added in-line. Atrial septostomy should be performed by an experienced catheterization laboratory during ECLS support in the case of incomplete left atrial/ventricular unloading, in order to prevent pulmonary hemorrhage. 19 At our institution, ECLS has been used successfully to provide temporary right ventricular assist (RVA[D]) after implantation of a LVAD, and is our RVAD of choice. We have used ECLS to treat severe pulmonary capillary leak syndrome secondary to a protamine reaction during LVAD implantation, and also in a similar situation (related to OKT3-induced cytokine release syndrome) after cardiac transplantation. Biventricular support can be achieved through venoarterial cannulation. It can be quickly implemented in cardiac arrest situations, particularly in the case of severe, uncontrollable ventricular arrhythmias.
An additional advantage to ECLS is that it is portable (our ECLS team routinely travels to outlying hospitals where ECLS is initiated, and the patient is transported to our institution by ground or air Centrifugal Pumps (Sarns Delphin ® and Biomedicus ® pumps). These devices (CPs) are commonly used as the pump in cardiopulmonary bypass circuits. They are non-pulsatile devices that use centrifugal force to draw in and propel blood via inflow and outflow cannulae that enter the body through subcostal incisions. CPs can be used for uni-or biventricular support, can be implanted at any cardiac surgery center, are inexpensive, and are portable for patient transfer. They are best used for short periods of support (hours to days), hemolysis being the rate-limiting factor. These devices are frequently used in combination with intra-aortic counterpulsation. Systemic heparinization is required. Bedside operation requires the presence of a perfusionist. Use of this device requires systemic anticoagulation. Heparin is administered after surgical bleeding is controlled, and is generally changed to warfarin during long-term use. Use of this device is primarily restricted to tertiary/transplant centers, as it requires expertise and resources not available in community hospitals. Patients can be discharged from the hospital while being supported by this device.
ABIOMED BVS

HeartMate ® IP-LVAS and VE-LVAS (Thermo Cardiosystems Inc., Woburn, MA).
There are actually two different HeartMate LVAD systems. Both consist of an implantable blood pump, which comprises a titanium alloy housing that contains a pusher plate behind a flexible polyurethane diaphragm. The inflow cannula is attached to the left ventricular apex, and the outflow cannula is anastomosed to the ascending aorta. Porcine valves within each cannula maintain unidirectional blood flow. The device is implanted in the left upper quadrant, either within the abdominal cavity or in a preperitoneal pocket, depending on the preference and experience of the surgeon.
One of the unique features of this device is that all blood-contacting surfaces (except the cannulae) are textured to promote the formation of a tightly adherent biologic pseudo-neointima, which allows blood to contact only a biologic surface. The titanium half of the interior of the device is lined with sintered titanium microspheres. The polyurethane half of the interior is similarly irregular. As a result, this device boasts an extraordinarily low thromboembolic rate of 2%-4%. 20,21 Systemic anticoagulation is not required, although daily aspirin is recommended.
The two devices differ in the way the pusher plate is activated. For the pneumatic model (IP-1000 LVAS), an external console pneumatically activates the pusher plate through a driveline that exits the body through a stab wound in the abdominal wall. In the Vented Electric model (VE LVAS), an electric motor is housed behind the pusher plate. The motor is coupled to the external controller and console through a driveline that exits the body through a stab wound in the abdominal wall. Because this device requires venting of air in the motor section of the device, the driveline also serves as a vent. Should a problem develop with the motor or other electric components of the device, the vent can be attached to a pneumatic console, and the device becomes a functional IP-LVAS.
Both devices can be operated in two different modes: fixed rate and automatic. In automatic mode, the cardiac output is determined by the device inflow (venous return) of the patient, allowing for increased flow during exercise. The IP-1000 LVAS can support flows of up to 11.7 L/min, and the VE LVAS up to 10 L/min. The external console of the IP-1000 LVAS is bulky, and despite the fact that these patients are quite mobile, they usually remain hospitalized because of the size of the external console. A smaller portable console, the HeartPak ® , is currently undergoing clinical trials. The VE LVAS console is smaller than the pneumatic console, and this device can be operated with two small, wearable In patients without LVADs, nitric oxide is not safe to use in the setting of significantly elevated left ventricular end-diastolic pressure. If pulmonary vascular resistance is precipitously decreased in this setting, left ventricular and pulmonary venous pressures can acutely rise secondary to the increase in right-to-left flow. This can result in severe pulmonary edema. 25 It is, therefore, imperative that left ventricular filling pressure be normalized prior to initiation of nitric oxide in this setting. However, in the absence of mitral stenosis, a LVAD will effect nearly complete pulmonary venous unloading, making nitric oxide safe in this setting.
Arrhythmias. Ventricular decompression through
use of a ventricular assist device can decrease myocardial ischemia and alleviate ventricular arrhythmias. Decreased atrial stretch can also reduce the frequency of atrial arrhythmias. Nonetheless, these patients are still at high risk for arrhythmias. Serious arrhythmias, such as ventricular tachycardia or fibrillation, can lead to hemodynamic instability in some patients. In other patients, malignant ventricular arrhythmias will have virtually no effect if Fontan-like right-to-left flow is adequate. 26 Right ventricular function and degree of pulmonary hypertension play a large role in the hemodynamic response of a patient to arrhythmia, particularly ventricular arrhythmia. Therefore, arrhythmias are less well tolerated in the first several days after device implantation because pulmonary vascular resistance is frequently elevated and right ventricular dysfunction is common in the immediate post-bypass physiologic state. Whether or not treatment for an arrhythmia is indicated depends less upon the type of ventricular assist device than on the patient's response to the arrhythmia. In the presence of an isolated LVAD, atrial fibrillation with loss of atrioventricular mechanical coupling is usually well tolerated. If serious arrhythmias are likely to have profound consequences in a patient who is to be supported with a LVAD, a better choice would be support with a BiVAD or TAH.
Treatment with antiarrhythmic agents during ventricular assist support is relatively commonplace. Since many of these patients are able to tolerate severe ventricular arrhythmias, some physicians are more willing to use antiarrhythmic agents that are potentially proarrhythmic (class IA and IC agents). Amiodarone (a class III agent) is frequently used. Although it is one of the safest and most effective antiarrhythmics in this group of patients, it should be used judiciously. The very long half-life of the drug can cause severe chronotropic insufficiency in the donor heart sinus node following the transplant, for which implantation of a permanent pacemaker may be required.
Direct current cardioversion or defibrillation can be performed in the presence of most ventricular assist devices, but should not be performed (unless absolutely necessary) without full knowledge of the consequences to the electrical systems of the specific device being used. Temporary deactivation of the device is desirable in order to prevent damage to the electrical circuits. For this reason, internal cardioverter-defibrillators are frequently explanted at the time of LVAD implantation.
Given the side effect profile of most antiarrhythmic agents, the occasional patient will be better off with a sustained arrhythmia than with antiarrhythmic therapy. Most patients with ventricular assist devices are systemically anticoagulated, so the risk of arrhythmia-associated embolic events is generally low. The exception to this rule is the HeartMate device, since systemic anticoagulation is not required. In the presence of significant arrhythmias, heparin and/or warfarin should be added to the regimen of HeartMate patients. Rates of infection differ from center to center, and have been quoted to be from 23%-58%, [27] [28] [29] with most large series reporting around 50%. A relatively high rate of fungal infections, usually candidal species, has been noted. It is unclear if any particular type of device is more prone to infectious complications.
Perioperative Hemodynamic
Many of the infectious complications can be treated with local debridement, appropriate wound care, and intravenous and/or oral antibiotics. An example of this would be a local driveline infection, which is fairly common. Even though minor, if not managed appropriately, driveline infections can ascend and become a major device pocket infection or mediastinitis. Major device-related infections can require explantation and exchange for a new device, particularly if persistent bacteremia is present. Many patients have been transplanted in the presence of a LVAD infection. In fact, at some centers, urgent transplantation, using marginal donors if necessary, is the treatment of choice for device infections. Outcomes in perhaps the largest series have been relatively favorable, with a survival rate to transplantation of 59%, as compared to 58% for patients without LVAD infections. 30 In this series, infections after transplantation were also not significantly different (35% vs. 28%). In rare cases, the best option is to explant the device and support the patient with medical therapy until the infection clears. In any case, infections will remain a problem at least until trancutaneous energy transfer or internal battery systems replace traditional drivelines.
Given the fact that these devices are endovascular, care should be taken to ensure appropriate antibiotic prophylaxis during dental, airway, gastrointestinal, and urogenital procedures. At the present time no data exist concerning what type of antibiotic coverage should be used. At a minimum, AHA guidelines for bacterial endocarditis (SBE) prophylaxis 31 for high risk patients (i.e., those with mechanical valves) should be followed.
Panel Reactive Antibodies. For patients awaiting
transplant, panel reactive antibody (PRA) assays are used to identify those who have been presensitized to HLA antigens. A presensitized state is usually associated with prior organ transplant, blood product transfusion, or multiparity. It has been shown that patients with PRA levels of greater than 10% are more likely to have difficulties with early rejection. 32 At many centers, it is typical to require a negative prospective lymphocytotoxic crossmatch prior to heart transplantation in the setting of a PRA of greater than 10%. The process of prospective crossmatching is time-consuming (which can jeopardize organ viability), and the wait time for a crossmatch-negative organ is typically significantly longer than if no crossmatch is required.
These issues are particularly pertinent to patients with ventricular assist devices, as there is a well known association between the presence of an assist device and elevated PRA levels. Why this occurs is not completely understood, but the association is likely to be a result of multiple factors. The use of blood products (particularly platelets) during implantation of these devices, the immunologic response of the patient to the biomaterials within the devices, and the length of exposure are all implicated. The development of a positive PRA after implantation of an assist device appears to be somewhat device-specific. Good data are sparse, but the literature suggests that short-term devices, such as the ABIOMED BVS 5000 ® , do not appear to stimulate this immunologic reaction. The long-term devices are more problematic.
The HeartMate devices appear to entail a higher incidence of elevated PRA levels than the other devices. In one series of 40 HeartMate patients, PRA levels were found to be elevated in 45% of patients. 33 The rate appeared to drop with the addition of leukocyte filters used to decrease the perioperative antigenic load. In another series of HeartMate patients, avoidance of cellular blood products did not eliminate this problem. 34 It is likely that the textured surface design of the HeartMate devices either modulates the immune system directly or plays some role in modulating the immunologic response to foreign human leukocyte antigen loads. Other devices, such as the CardioWest and Novacor, appear to carry intermediate risk, 35 although only limited studies have been performed to examine this issue as it relates to these devices.
Clinical strategies for dealing with this problem include use of leukocyte filters for cellular blood products before, during, and after LVAD implantation, with avoidance of blood products if possible, and the use of drugs (aspirin or pentoxifylline) that may down-regulate the immune response to antigenic stimuli (by preventing activation of nuclear factor kappaB in particular). If an elevated PRA is noted, treatment options include the use of intravenous immunoglobulin, plasmapheresis, cytotoxic drugs, and mycophenolate mofetil. We have avoided the last three options because of the heightened risk of infection in the presence of an assist device. Once a significant positive PRA level is noted, it is likely that the waiting time for an organ (and device support time) will be significantly longer because of the need for a negative crossmatch. At our institution, we have noted that patients who develop a positive PRA after HeartMate implantation do not appear to have a higher incidence of rejection as compared to controls and that 2-year survival does not appear to be affected. 36 For patients who are presensitized prior to placement of an assist device, use of a less immunogenically active device may, however, be considered.
Thromboembolic Events. Thromboembolic (TE)
rates have long been a weakness of mechanical circulatory devices. Rates of greater than 30% were commonly reported in the late 1980s. 37,38 However, design changes and improved anticoagulation regimens appear to have significantly reduced the risk, and continual improvements make it difficult to quote exact TE rates for each device. Rates for most nontextured devices vary from 8%-35%. 39, 40 More recent reviews support TE rates of 14% for the ABIOMED BVS 5000 ® device (personal communication, Doug McNair), and 8% for the Thoratec device, 40 with fewer TEs noted with ventricular cannulation than with atrial cannulation. TE rates for the Novacor device range from 10%-35%, 39, 41 although with recent cannula modifications this rate has been reduced to 5% 42 -12%. 43 The addition of antiplatelet agents may also contribute to the lower rates observed recently.
TE events plagued the early years (and earlier incarnations) of the CardioWest device. More recent data demonstrate TE rates that range from 0% 44 -26%. 45, 46 The recent improvements in TE rates with this device are probably related to more sophisticated anticoagulation regimens, which include warfarin, dypyridamole, pentoxifylline, aspirin, ticlopidine, and clopidogrel.
The HeartMate devices, with their textured surface technology, appear to consistently have lower TE rates. Most reports quote rates of 2%-4%. 20, 21 Survival Rates. In a recent report 47 on the worldwide experience with the HeartMate devices, survival rates (to transplant or explant) were noted to be 71% for the IP-1000 LVAS and 58% for the VE LVAS, with rates of 73% and 63%, respectively, in the U.S. 47 Survival rates at the Cleveland Clinic have been as high as 76%. 13 In our experience of 50 HeartMate implants, we have noted 80% survival to transplantation, with 97% survival to discharge after transplantation. In the Vented Electric bridgeto-transplant trial, the 1-year post-transplant survival was 84% (personal communication, Laura Damme).
Over one half of deaths during LVAD support with any of the assist devices occur within the first month of implantation. The HeartMate Registry data illustrate this well (similar data exist for the other LVADS). When these perioperative deaths are excluded, worldwide survival is 87% for the IP-1000 LVAS and 79% for the VE LVAS, with rates of 88% and 84%, respectively, in the U.S. 47 This highlights the importance of proper preoperative screening and the possible use of ECLS as a bridge to LVAD in selected high risk patients.
In a review of international experience with the CardioWest device, a survival to transplantation rate of 69%, and post-transplant survival to discharge rate of 92% were reported. 48 In a smaller series of U.S. recipients of this device, a survival rate of 93% was noted, with a post-transplant discharge to home rate of 96%. 46 In this series, survival to discharge for the control group of patients (no device) was only 39%.
In a recent review of the worldwide experience of the Novacor device, 58% of patients survived to transplant and 89% of these patients survived to discharge. 42 In this review, 768 patients were implanted between 1984 and 1997. More recent data from a registry of 22 U.S. centers (129 patients) demonstrate a survival to transplantation rate of 76%. 49 The University of Pittsburgh experience was a survival to transplant rate of 72%, with 84% of these patients surviving to discharge. 42 Worldwide results for the Thoratec VAD System (57% BiVAD, 40% LVAD, 3% RVAD) demonstrate a survival to transplant rate of 60%, with 86% of these patients surviving to discharge. 50 Overall post-transplant survival rates are comparable to the International Society for Heart and Lung Transplantation (ISHLT) Registry data. No relationship has been found between duration of VAD support and survival after transplantation.
From 1984 through 1996, a total of 1286 devices (Thoratec, Novacor, HeartMate, and CardioWest) were implanted worldwide as bridges to transplantation. Overall survival to transplant during that era was 60%, with 88.5% of those surviving to discharge. After transplantation, survival to discharge was similar for all devices, with rates between 81% and 92%. 51 Survival rates vary greatly from study to study, and from center to center (even when the same device is compared). Device improvements, increased clinical expertise, better patient selection, and improved preventive strategies render data about survival rates quickly out of date and survival comparisons between devices limited.
Which Device Should I Use? Given the relatively small numbers of patients who require longterm mechanical support, the rapidly evolving technologies, and the large financial barriers, it is unlikely that a randomized trial of existing devices will ever be done. Also, it is likely that few, if any, cardiac surgery centers will be able to support the use of more than two or three types of devices. All present forms of mechanical assist devices have individual strengths and weaknesses, some of which are described above. None of the devices is clearly superior to the rest, and each fills a particular niche. Given these facts, the question of which devices to use can be best answered by the type of patient most likely to be seen at a given institution, the capabilities of that institution, and the comfort level of all involved medical staff with each device.
As As another example, Thoratec Laboratories is in the process of developing an implantable ventricular assist device, or IVAD. 50 The design of the pump is basically the same as that of the company's existing blood pump, with the advantage of having only one exiting drive line as opposed to two exiting blood cannulae. It will be significantly smaller than the Novacor or HeartMate devices, and therefore will benefit smaller patients.
As for new technology, the trend in the near future is for transcutaneous energy transfer systems that will eliminate the need for drivelines. The first human implant of the LionHeart™ occurred on October 26, 1999 in Germany. The LionHeart LVAS, developed by Arrow International in collaboration with Pennsylvania State University, utilizes a transcutaneous energy transfer system, implanted batteries, controller, and electrically powered blood pump equipped with two tilting-disk valves. The device is entirely implantable. A compliance chamber, placed in the left pleural space, allows for device venting. A subcutaneous access port allows for periodic percutaneous needle gas equilibration in order to maintain gas volume within the system. Energy is transferred via an external skin coil that is placed over the internal coil, and internal batteries allow for 20 minutes of untethered activity. The external battery pack allows for 2-3 hours of power for mobile operation away from the floor-based power charger. Because of the presence of mechanical valves, patients will require long-term systemic anticoagulation. This device has been designed as destination therapy, and not for bridge to transplant or recovery, and is intended for class IV patients who are considered ineligible for heart transplantation. A clinical trial of this device in a total of 30 patients is ongoing in Europe. It is expected that the FDA will approve this device for clinical trials in the U.S. in the next few months.
Thoratec Laboratories is currently developing a muscle-powered ventricular assist device, or MVAD, 50 designed to be used as an alternative to transplantation. The device converts the mechanical energy of a stimulated latissimus dorsi into hydraulic energy that drives the VAD. It is designed to be completely internal and free of external drivelines.
ABIOMED, Inc. is in the process of developing a new TAH called the AbioCor TM . 57 This device will incorporate two artificial ventricles, polyurethane valves, a motor-driven hydraulic pumping system, a transcutaneous energy transmission system, and an externally worn battery pack. It is being designed as an alternative to transplant. Clinical trials of this device, as well as the Penn State TAH (which will also utilize a transcutaneous energy transmission system) will likely begin within the next year or two.
Another technological advance that will be in clinical use very soon is the axial flow pump. Several groups are in the process of developing this type of device. The NASA/DeBakey VAD TM system, consists of a titanium inflow cannula that connects the pump to the apex of the left ventricle, a miniaturized axial flow pump, and a vascular graft outflow cannula that connects the pump to the ascending aorta. The device has a rotor speed of 10,000 rpm and can deliver 5 L/min. A driveline connects the device to an external controller system. This device is the first axial flow device used in humans. 58 Thus far it has been tested in approximately two dozen patients as a bridge to transplantation. At present, this device is under investigation in Europe.
The Jarvik-2000 59 device is a compact axial flow impeller blood pump that is inserted into the left ventricle through a sewing cuff anchored into the left ventricular apex. A Dacron outflow graft is anastomosed into the descending thoracic aorta. The device is 2.5 x 5.5 cm, weighs 85 g, and has a displacement volume of 25 ml (a pediatric version of the same pump is even smaller). It operates at speeds of 8000-12,000 rpm and can provide nonpulsatile blood flow of 8 L/min. There are no valves. Although it is designed as a LVAD, it is possible that it can be configured to function as a RVAD or BiVAD. A distinct advantage of this device is that it is quiet, unlike existing devices. The present incarnation of this device has a small driveline cable; however, a transcutaneous energy system will likely be available in the near future. Animal studies with this device have been promising. The first implantation of the Jarvik-2000 in a human occurred several weeks prior to the completion of this article.
Thermo Cardiosystems is currently developing a similar axial flow impeller device, the Nimbus/TCI device, also called the HeartMate II. 20 Clinical trials using this device in humans are scheduled to begin in the summer of 2000 in Israel. The Sun Medical/HIJ/Waseda/Pittsburgh axial flow pump is also under development. These new devices will broaden our patient population to include smaller adults as well as children.
Conclusion
As we enter the new millennium, our options for treating patients with end stage heart failure, surgical as well as medical, will continue to expand. Hundreds of thousands of patients will benefit from the future generations of devices that arise from our present-day cardiac assist technology.
